- The probability of death will double in the next 10 years if middle-aged and elderly people can’t stand on one foot for 10 seconds
- Maradona death: Medical team members will be tried for alleged murder
- Tuberculosis infection in Singapore: About 30% of the 574 people in the same community positive
- Swollen axillary lymph nodes associated with the COVID-19 vaccine last longer than initially reported
- How to relieve the fatigue symptoms of patients with Parkinson’s disease?
- Frontiers in Oncology: Mushroom extract can clear HPV infection
Sterilize with bacteria to relieve itching and improve symptoms!
Sterilize with bacteria to relieve itching and improve symptoms! Randomized double-blind phase I trial shows new hope for the treatment of eczema.
Human skin is the “ideal home” for bacteria. The skin of a healthy person is covered with about 1,000 kinds of bacteria. Most of the resident bacteria will not pose a threat to us, but for some eczema patients, some bacteria will cause them big trouble.
Eczema is clinically called atopic dermatitis (AD), which is a chronic and recurring inflammatory skin disease. Eczema is relatively common in children and currently affects approximately 15% to 20% of children worldwide. The clinical features of eczema are severe itching and defects in the epidermal barrier, which can have a serious impact on the quality of life of patients, especially in winter.
Recently, in a study published in “Nature Medicine”, a research team led by the University of California, San Diego, isolated a kind of bacteria from healthy human skin, and confirmed through randomized double-blind clinical trials that it can effectively treat the most common Eczema.
Eczema is mostly related to bacterial infections, including Staphylococcus aureus. Previous studies have found that Staphylococcus aureus colonizes the skin of patients with eczema and exacerbates symptoms through pro-inflammatory.
In this new study, researchers isolated more than 8,000 strains of coagulase-negative Staphylococcus (CoNS) from the skin of healthy individuals to identify strains that can inhibit the growth of Staphylococcus aureus.
The researchers also evaluated other characteristics of these strains, including weakened epidermal barrier damage, sensitivity to common antibiotics, and the ability to form biofilms. Through screening, they finally identified a strain called Staphylococcus humana A9 (ShA9), which has the potential to treat eczema.
Then, the researchers performed experimental treatments in a mouse model of eczema. They mixed ShA9 with an unscented lotion into an ointment, and then applied it to the mice twice a day for three days. The eczema of the mice treated with ShA9 was basically cured (see the picture below).
Researchers found that ShA9 can inhibit skin inflammation, not just kill Staphylococcus aureus.
Subsequently, the researchers carried out the first randomized double-blind phase I clinical trial in humans for the treatment of eczema against this specific bacteria to further study its safety and mechanism of action.
In 54 patients with moderate to severe eczema who were positive for Staphylococcus aureus, the researchers treated their skin lesions on their forearms with ShA9. Use skin swabs to collect live bacteria, microbial DNA and RNA from skin lesions and non-lesion sites on the 4/7 (4 hours after the last medication)/8/9/11 days after treatment for 1 hour, and for detection .
Evaluation of all patients treated with ShA9 showed that there was no significant difference in the severity of eczema, but there was a significant reduction in Staphylococcus aureus. The researchers found that ShA9 could not directly kill some Staphylococcus aureus strains on the patient’s skin, but the mRNA expression of all strains of virion was suppressed.
The results after treatment showed that two-thirds of the patients in the ShA9 treatment group had improved eczema severity, including relief of itching and reduction of inflammatory symptoms. These observations prove the safety and potential benefits of bacteria in the treatment of eczema.
The corresponding author of the study, Professor Richard Gallo, director of the Department of Dermatology at the University of California, San Diego School of Medicine, said: “This is a safety study. Participants who received bacterial treatment showed improvement in their eczema and no adverse events.”
The study’s co-author and American National Jewish Health Allergy and Immunologist Donald Leung said: “This study uses a unique method that uses beneficial bacteria to target the harmful Staphylococcus aureus.
We hope this will help eczema sufferers to clear the harmful bacteria that cause inflammation on the skin. Future research will determine whether this new ointment can be used for a long time to reduce the severity of eczema and improve the quality of life of patients. “
Gallo said: “We have determined that this method is safe to treat eczema, and it is easy to use because it is just an ointment and avoids the side effects of steroids and other immune system drugs.”
(source:internet, reference only)